Haleon is seeing short-seller pressure
Haleon PLC (LSE:HLN), known for its Sensodyne and Advil products, is currently dealing with a significant short-seller attack from Marshall Wace, which has taken a position worth around £150 million.
It marks the company's first major short-seller challenge since its spinoff from GSK and Pfizer two years ago.
Despite the reports, the stock remained relatively stable closing Monday at 328.4p, up 0.18%.
